NIR-II biomimetic nanoplatform optogenetic CD274 editing of HNSCC immunogenicity for enhanced photoimmunotherapy.

Mater Today Bio · 2026 · PMC12857282 · PMID 41624538

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The tumor volumes in treatment groups ARP + L and ARPC + L exhibited a decreasing trend on day five and continued to decline throughout the treatment cycle.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.